August 28, 2015 – FDA Drug Safety Communication issued over reports of severe joint pain in patients treated with DPP-4 inhibitor diabetes drugs.
August 28, 2015 – FDA Drug Safety Communication issued over reports of severe joint pain in patients treated with DPP-4 inhibitor diabetes drugs.